Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00136942
Status:
COMPLETED
Last Update Posted:
2021-02-18
First Post:
2005-08-25
Brief Title:
A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol
Sponsor:
Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization:
Pfizer
Study Overview
Official Title:
A Multicenter 6-Week-Treatment Open-Label Study Assessing The Percentage Of Hyperlipidemic Patients Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin
Status:
COMPLETED
Status Verified Date:
2021-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ACTFAST SWISS
Brief Summary:
The proportion of patients achieving LDL-C target as defined by Swiss cholesterol recommendations AGLA-recommendations across starting doses of 10 mg 20 mg 40 mg and 80 mg of atorvastatin
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None